Sanjeev Vaishnavi, MD
Neurology · Philadelphia, PANPI 1669790754
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,725 of the $7,215 with a category attached, or 65.5%. Eli Lilly accounts for 83.7% of it on its own, with 2 other manufacturers making up the rest.
Across 16 payments — averaging $450.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$6K
- Lilly USA, LLC$993
- Eisai Inc.$186
Across 100 payments — averaging $16,421 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.1M
- Eisai Inc.$344K
- Novartis$141K
- Biogen$55K
What the payments were for
- Consulting fees$4,72565%
- Travel & lodging$2,04628%
- Food & beverage$4306%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 4 | $6,037 |
| Lilly USA, LLC | 9 | $993 |
| Eisai Inc. | 3 | $186 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$125
How this compares
$7,215 in reported general payments places this provider in the 75th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl ErMemantine Hcl | 213 | $19,524 |
| Donepezil Hcl | 250 | $2,881 |
| Memantine Hcl | 32 | $1,568 |
| Sertraline Hcl | 108 | $1,197 |
| Quetiapine Fumarate | 50 | $1,099 |
| Escitalopram Oxalate | 13 | $109 |
| Trazodone Hcl | 11 | $67 |
Paid to pharmacies, not to this prescriber.
Other neurology in Philadelphia
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Stephanie Nahas-GeigerPhiladelphia$786K
- Amit Bar-OrPhiladelphia$596K
- Stephen SilbersteinPhiladelphia$428K
- Joseph BergerPhiladelphia$384K
- Sami KhellaPhiladelphia$285K
- Clyde MarkowitzPhiladelphia$274K
- Matthew SternPhiladelphia$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.